Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Atazanavir GPO vs REYATAZ Under Fed Conditions in Healthy Adults
TCTR20180217003Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of atazanavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Government Pharmaceutical Organization. Primary endpoint: Bioequivalence based on pharmacokinetic parameters. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
atazanavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20180217003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180217003.